Targeted Cancer Therapy Data to Debut at ESMO Congress
The Phase 1/2 study explores a new combination treatment for patients with specific metastatic lung and pancreatic cancers.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Do you trust biotechnology company clinical data updates to inform your investment decisions?
Tango Therapeutics will present early-stage clinical data on a combination therapy for specific lung and pancreatic cancers during the ESMO Congress in Madrid starting October 23, 2026. The findings concern a Phase 1/2 trial for patients with MTAP-deleted, RAS-mutant tumors.
Why it matters
This research explores a new combination therapy approach for metastatic cancers that currently have limited treatment options. The trial data offers a look at how this targeted approach performs in a clinical setting for these specific genetic mutations.
The upcoming presentation details a Phase 1/2 clinical study of vopimetostat combined with daraxonrasib or zoldonrasib, identified by abstract 3149P. These preliminary results, based on a data cutoff of April 3, 2026, specifically evaluate treatment in patients with MTAP-deleted RAS-mutant metastatic PDAC and NSCLC.
The players
Tango Therapeutics
A biotechnology company focused on developing precision cancer medicines using synthetic lethality.
Alexander I. Spira
An oncologist and researcher specializing in the development of new treatments for lung and other thoracic cancers.
The details
The treatment approach leverages synthetic lethality, a genetic principle where the simultaneous disruption of two genes leads to cell death, while the loss of only one is survivable. By targeting MTAP-deleted tumors that also carry RAS mutations, the researchers aim to selectively kill cancer cells while sparing healthy tissue. The study investigates whether combining vopimetostat with other agents can enhance these therapeutic effects in metastatic pancreatic and non-small cell lung cancers.
Timeline
• October 19, 2026: Abstracts become available on the ESMO website.
• October 23, 2026: The ESMO Congress begins and Tango Therapeutics hosts an investor webcast.
• October 25, 2026: Alexander I. Spira presents the study poster.
• October 27, 2026: The ESMO Congress concludes.
Health Landscape
The ESMO Congress serves as a primary international forum for unveiling the latest clinical advancements in oncology. This presentation continues the shift toward precision, mutation-specific cancer therapies that aim to move beyond traditional, broad-spectrum treatment approaches.
Patients with MTAP-deleted, RAS-mutant metastatic cancers should discuss the eligibility criteria for current clinical trials with their oncologist. Understanding whether a tumor carries specific genetic mutations is a vital step in determining the range of potential treatment options.
The takeaway
This study highlights the ongoing effort to use specific genetic markers to tailor cancer treatment. Patients should consult their physician about biomarker testing to see if their specific cancer profile aligns with emerging targeted therapy research.
What happens next
A replay of the October 23, 2026, investor webcast will be available on the Tango Therapeutics website for at least 30 days following the event.
Further reading
For more on the current research landscape, visit our Cancer section.
More information
View upcoming updates on the Tango Therapeutics investor events portal.
Live Poll
Do you trust biotechnology company clinical data updates to inform your investment decisions?
